Omalizumab treats multi-food allergy better than oral immunotherapy, study finds

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.

Facebook Comments